All In Biotech

Drug Trial Radar · NCT07600476

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Jul 3, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Kupando GmbHIndustry
Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Conditions

  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Merkel Cell Carcinoma of Skin
  • Basal Cell Carcinoma of Skin

Interventions

  • KUP-101ADrug

    Intravenous infusion of KUP-101A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and related TEAEsTime frame: From enrollment until three months after last dose administration
  2. Proportion of patients with dose-limiting toxicities (DLTs)Time frame: From start of treatment until one week after last dose administration.
  3. Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test resultsTime frame: From enrollment until three months after last dose administration
  4. Incidence of abnormal clinical findings in 12-lead ECG parameters and vital signsTime frame: From enrollment until three months after last dose administration

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie

    Munich, Bavaria, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany · Recruiting

  • Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie

    Marburg, Hesse, Germany · Recruiting

  • Fachklinik Hornheide

    Münster, North Rhine-Westphalia, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.